Last reviewed · How we verify

S-ketamine infusion outpatient setting

Erasmus Medical Center · Phase 1 active Small molecule

S-ketamine infusion outpatient setting is a Small molecule drug developed by Erasmus Medical Center. It is currently in Phase 1 development. Also known as: ketamine, esketamine.

At a glance

Generic nameS-ketamine infusion outpatient setting
Also known asketamine, esketamine
SponsorErasmus Medical Center
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about S-ketamine infusion outpatient setting

What is S-ketamine infusion outpatient setting?

S-ketamine infusion outpatient setting is a Small molecule drug developed by Erasmus Medical Center.

Who makes S-ketamine infusion outpatient setting?

S-ketamine infusion outpatient setting is developed by Erasmus Medical Center (see full Erasmus Medical Center pipeline at /company/erasmus-medical-center).

Is S-ketamine infusion outpatient setting also known as anything else?

S-ketamine infusion outpatient setting is also known as ketamine, esketamine.

What development phase is S-ketamine infusion outpatient setting in?

S-ketamine infusion outpatient setting is in Phase 1.

Related